The effect of NOD2 Polymorphism on postsurgical recurrence in crohn's disease: A systematic review and meta-analysis of available literature

Inflammatory Bowel Diseases

Volumn 19, Issue 4, 2013, Pages 1099-1105

  Solon, Jacqueline G ^a   Burke, John P ^a   Walsh, Stewart R ^a,b   Coffey, J Calvin ^a,b  

^a UNIVERSITY HOSPITAL LIMERICK   (Ireland)

^b UNIVERSITY OF LIMERICK   (Ireland)

Author keywords

Crohn's disease; Nod2; Surgical recurrence'

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15;

CLINICAL TRIAL; CROHN DISEASE; DNA POLYMORPHISM; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; META ANALYSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENT DISEASE; REOPERATION; REVIEW; SYSTEMATIC REVIEW; DISEASE ASSOCIATION; GENETIC ASSOCIATION; INTESTINE RESECTION; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM;

COHORT STUDIES; CROHN DISEASE; HUMANS; META-ANALYSIS AS TOPIC; NOD2 SIGNALING ADAPTOR PROTEIN; POLYMORPHISM, GENETIC; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RECURRENCE;

EID: 84876375769     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e3182813391     Document Type: Review

References (43)

1. Sachar DB. Recurrence rates in Crohn's disease: predicting the future and predicting the past. Gut. 2006;55:1069-1070.
2. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg. 2000;231:38-45.
3. Olaison G, Smedh K, Sjodahl R. Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut. 1992;33:331-335.
4. Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut. 1984;25:665-672.
5. Lock MR, Farmer RG, Fazio VW, et al. Recurrence and reoperation for Crohn's disease: the role of disease location in prognosis. N Engl J Med. 1981;304:1586-1588.
6. Hampe J, Grebe J, Nikolaus S, et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet. 2002;359:1661-1665.
7. Cunningham MF, Docherty NG, Coffey JC, et al. Postsurgical recurrence of ileal Crohn's disease: an update on risk factors and intervention points to a central role for impaired host-microflora homeostasis. World J Surg. 2010;34:1615-1626.
8. Ahmed T, Rieder F, Fiocchi C, et al. Pathogenesis of postoperative recurrence in Crohn's disease. Gut. 2011;60:553-562.
9. D'Haens GR, Vermeire S, Van Assche G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology. 2008;135:1123-1129.
10. Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology. 2009;136: 441-450; e441;quiz 716.
11. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989;111:641-649.
12. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6- mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2009:CD000545.
13. Siegel CA, Hur C, Korzenik JR, et al. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol. 2006;4: 1017-1024; quiz 1976.
14. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucinerich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411:599-603.
15. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603-606.
16. Inohara N, Ogura Y, Fontalba A, et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem. 2003;278:5509-5512.
17. Economou M, Trikalinos TA, Loizou KT, et al. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol. 2004;99:2393-2404.
18. Lesage S, Zouali H, Cezard JP, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet. 2002;70:845-857.
19. Cuthbert AP, Fisher SA, Mirza MM, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology. 2002;122:867-874.
20. Ahmad T, Armuzzi A, Bunce M, et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology. 2002;122: 854-866.
21. Abreu MT, Taylor KD, Lin YC, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology. 2002;123:679-688.
22. Maconi G, Colombo E, Sampietro GM, et al. CARD15 gene variants and risk of reoperation in Crohn's disease patients. Am J Gastroenterol. 2009; 104:2483-2491.
23. Alvarez-Lobos M, Arostegui JI, Sans M, et al. Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg. 2005;242:693-700.
24. Buning C, Genschel J, Buhner S, et al. Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation. Aliment Pharmacol Ther. 2004;19:1073-1078.
25. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
26. Dunne C, Burke JP, Morrow M, et al. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol. 2009;27:1615-1620.
27. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127:820-826.
28. Onnie CM, Fisher SA, Prescott NJ, et al. Diverse effects of the CARD15 and IBD5 loci on clinical phenotype in 630 patients with Crohn's disease. Eur J Gastroenterol Hepatol. 2008;20:37-45.
29. Renda MC, Orlando A, Civitavecchia G, et al. The role of CARD15 mutations and smoking in the course of Crohn's disease in a Mediterranean area. Am J Gastroenterol. 2008;103:649-655.
30. Polito JM 2nd, Childs B, Mellits ED, et al. Crohn's disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology. 1996;111:580-586.
31. Satsangi J, Grootscholten C, Holt H, et al. Clinical patterns of familial inflammatory bowel disease. Gut. 1996;38:738-741.
32. Bayless TM, Tokayer AZ, Polito JM 2nd, et al. Crohn's disease: concordance for site and clinical type in affected family members-potential hereditary influences. Gastroenterology. 1996;111:573-579.
33. Colombel JF, Grandbastien B, Gower-Rousseau C, et al. Clinical characteristics of Crohn's disease in 72 families. Gastroenterology. 1996;111: 604-607.
34. Achkar JP, Duerr R. The expanding universe of inflammatory bowel disease genetics. Curr Opin Gastroenterol. 2008;24:429-434.
35. Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet. 2001;357:1925-1928.
36. Ioannidis JP, Gwinn M, Little J, et al. A road map for efficient and reliable human genome epidemiology. Nat Genet. 2006;38:3-5.
37. Little J, Higgins JP, Ioannidis JP, et al. Strengthening the Reporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. PLoS Med. 2009;6:e22.
38. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748.
39. Mahid SS, Hornung CA, Minor KS, et al. Systematic reviews and metaanalysis for the surgeon scientist. Br J Surg. 2006;93:1315-1324.
40. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
41. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
42. Seiderer J, Schnitzler F, Brand S, et al. Homozygosity for the CARD15 frameshift mutation 1007fs is predictive of early onset of Crohn's disease with ileal stenosis, entero-enteral fistulas, and frequent need for surgical intervention with high risk of re-stenosis. Scand J Gastroenterol. 2006;41: 1421-1432.
43. Adler J, Rangwalla SC, Dwamena BA, et al. The prognostic power of the NOD2 genotype for complicated Crohn's disease: a meta-analysis. Am J Gastroenterol. 2011;106:699-712.